Calix (CALX) CPO receives 195,000 performance-based stock options

Rhea-AI Filing Summary

Calix Chief Product Officer Shane Eleniak received a grant of stock options covering 195,000 shares of common stock. The options have an exercise price of $39.68 per share.

The award was originally granted on January 31, 2025 as a performance-based option. On February 12, 2026, the Compensation Committee confirmed that the performance criteria for 100% of the grant had been achieved. The option vests 25% on January 31, 2026, with the remaining 75% vesting in equal quarterly installments over 36 months from that date, subject to Eleniak’s continued employment with Calix.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eleniak Shane Todd Marshall

(Last) (First) (Middle)

C/O CALIX, INC.

3155 OLSEN DRIVE, SUITE 450

(Street)

SAN JOSE CA 95117

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CALIX, INC [ (CALX) ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$39.68	02/12/2026		A		195,000		01/31/2026(1)	01/31/2035	Common Stock	195,000	$0	195,000	D

Explanation of Responses:

1. On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.

Remarks:

	/s/ Tom Gemetti as Attorney-in-fact for Shane Eleniak	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Calix (CALX) report in this Form 4 for its Chief Product Officer?

Calix reported that Chief Product Officer Shane Eleniak received a performance-based stock option for 195,000 shares at an exercise price of $39.68. The award reflects equity compensation tied to performance and continued employment with the company.

When were the performance conditions satisfied for Shane Eleniak’s Calix (CALX) option grant?

The Compensation Committee determined on February 12, 2026 that the performance criteria governing 100% of Shane Eleniak’s 195,000-share option grant had been achieved. This confirmation allowed the performance-based stock options to begin vesting under the stated schedule.

How does the 195,000-share Calix (CALX) stock option vest for the Chief Product Officer?

The option vests 25% on January 31, 2026, with the remaining 75% vesting quarterly in equal installments over 36 months from January 31, 2026. Vesting is conditioned on Shane Eleniak’s continued employment with Calix.

What is the exercise price of the Calix (CALX) stock option granted to Shane Eleniak?

The performance-based stock option granted to Shane Eleniak has an exercise price of $39.68 per share. This is the price at which he can purchase Calix common stock when vested options are exercised in the future.

Is Shane Eleniak’s Calix (CALX) option grant a performance-based award?

Yes. The Form 4 states that on January 31, 2025 Eleniak received a performance-based option for 195,000 shares. On February 12, 2026, the Compensation Committee confirmed that performance criteria for the full grant had been achieved.

Who is the reporting person in this Calix (CALX) Form 4 and what is their role?

The reporting person is Shane Todd Marshall Eleniak, who serves as Chief Product Officer of Calix. The Form 4 records his acquisition of performance-based stock options as part of his equity compensation package.